FDC Limited , a prominent pharmaceutical company, has announced a significant change in its top management. The company's Board of Directors has accepted the resignation of Vijay Dharmadatt Bhatt from his position as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective October 20, 2025. Simultaneously, the Board has appointed Vishal Shah as the new CFO and KMP, with his tenure commencing on October 24, 2025.

Resignation Details

Mr. Bhatt, in his resignation email, cited the pursuit of better prospects as the reason for his departure. The company acknowledged his valuable contributions during his tenure and expressed best wishes for his future endeavors.

New Appointment

The appointment of Vishal Shah as the new CFO and KMP was approved based on recommendations from the Nomination and Remuneration Committee and the Audit Committee. Mr. Shah brings a wealth of experience to his new role, with approximately 20 years of work in various finance portfolios within the pharmaceutical industry.

Key Information

Here's a summary of the key details regarding this management change:

The transition in the CFO position is a significant development for FDC Limited. Mr. Shah's extensive experience in various aspects of finance within the pharmaceutical industry suggests that he is well-positioned to contribute to the company's financial strategy and operations going forward.

FDC Limited has complied with the necessary regulatory requirements by disclosing this information under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirement) Regulations, 2015. The company's proactive approach in managing this transition demonstrates its commitment to maintaining transparency with its stakeholders and ensuring a smooth handover of financial leadership.

FDC Ltd, a prominent pharmaceutical company, has achieved a significant milestone in its expansion into the U.S. market. The company recently received approval from the United States Food and Drug Administration (U.S. FDA) for its Pilocarpine Hydrochloride Eye Drops, marking a crucial step in its growth strategy.

Product Details

The U.S. FDA has granted approval for FDC Ltd's Pilocarpine Hydrochloride Ophthalmic Solution USP in three different concentrations:

This approval allows FDC Ltd to market these eye drop formulations in the United States, potentially opening up new revenue streams for the company.

Regulatory Compliance

In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, FDC Ltd has duly informed the BSE Limited and the National Stock Exchange of India Ltd about this development. The company's commitment to transparency is evident in its prompt disclosure of this material information to the stock exchanges.

Market Implications

The U.S. FDA approval is a significant achievement for FDC Ltd, as it:

1. Expands the company's product portfolio in the U.S. market
2. Potentially increases revenue opportunities
3. Enhances the company's reputation in the global pharmaceutical industry

Investors and market watchers may view this development positively, as it demonstrates FDC Ltd's capability to meet stringent U.S. FDA standards and its strategic focus on expanding its presence in the U.S. pharmaceutical market.

As FDC Ltd prepares to introduce these eye drop formulations to the U.S. market, stakeholders will likely keep a close watch on the company's performance and any subsequent impact on its financial results in the coming quarters.